Request for SCANCO micro-CT 40 Multi-User Bone Studies

Lian, Jane B.

Abstract

The goal of this proposal is to acquire funds to purchase a Scanco

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Center for Research Resources (NCRR)
• Type: Biomedical Research Support Shared Instrumentation Grants (S10)
• Project #: 1S10RR023540-01A1
• Application #: 7389778
• Study Section: Special Emphasis Panel (ZRG1-MOSS-G (30))
• Program Officer: Tingle, Marjorie
• Project Start: 2008-02-01
• Project End: 2009-01-31
• Budget Start: 2008-02-01
• Budget End: 2009-01-31
• Support Year: 1
• Fiscal Year: 2008
• Total Cost: $276,700

Institution

• Name: University of Massachusetts Medical School Worcester
• Department: Anatomy/Cell Biology
• Type: Schools of Medicine
• DUNS #: 603847393
• City: Worcester
• State: MA
• Country: United States
• Zip Code: 01655

Publications

Huang, Henry; Skelly, Jordan D; Ayers, David C et al. (2017) Age-dependent Changes in the Articular Cartilage and Subchondral Bone of C57BL/6 Mice after Surgical Destabilization of Medial Meniscus. Sci Rep 7:42294

Ramo, Kasmir; Sugamura, Koichi; Craige, Siobhan et al. (2016) Suppression of ischemia in arterial occlusive disease by JNK-promoted native collateral artery development. Elife 5:

Dutta, Anindita; Li, Jing; Lu, Huimin et al. (2014) Integrin ?v?6 promotes an osteolytic program in cancer cells by upregulating MMP2. Cancer Res 74:1598-608

Gaur, Tripti; Hussain, Sadiq; Mudhasani, Rajini et al. (2010) Dicer inactivation in osteoprogenitor cells compromises fetal survival and bone formation, while excision in differentiated osteoblasts increases bone mass in the adult mouse. Dev Biol 340:10-21

Jones, Marci D; Liu, Julie C; Barthel, Thomas K et al. (2010) A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin Cancer Res 16:4978-89

Pratap, Jitesh; Akech, Jacqueline; Wixted, John J et al. (2010) The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Mol Cancer Ther 9:3210-20